Look back at pharma news in the week to December 11, 2020

13 December 2020

By Barbara Obstoj-Cardwell. Editor

COVID-19, regulatory news and M&A activity featured last week, with Amgen gaining Breakthrough Therapy designation for sotorasib (AMG 510), its candidate for lung cancer patients with KRAS G12C mutations. Pfizer and BioNTech received a positive vote for their COVID-19 vaccine candidate BNT162b2 from a US Food and Drug Administration advisory panel, followed the next day with an emergency use authorization from the FDA. Johnson & Johnson’s Janssen unit filed for European Medicines Agency approval of its PP6M, a new formulation of paliperidone palmitate for schizophrenia. Also of significance was Gilead Sciences’ announcement of its fifth M&A deal this year, with an agreement to acquire Germany’s MYR GmbH for $1.39 billion. Also, Boehringer Ingelheim announced a $1.4 billion acquisition of Swiss immune-oncology company NBE Therapeutics.

SVBL forecasts Amgen’s KRAS inhibitor sotorasib sales likely to be $1.0 billion in 2025

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK